Abstract: A facility for the production of radionuclides based photonuclear irradiation, comprising: an electron accelerator (1), producing an electron beam (2); a converter target assembly (21) with a converter target (20) that converts the electron beam (2) to Bremsstrahlung photons (15); a production target (17), irradiated by the Bremsstrahlung photons (15) and thereby producing said radionuclides.

Abstract: Multi-component systems and methods for determining the proximity of surgical tools to key anatomical features are provided. The inventive systems and methods can be applied in any surgical procedure requiring precision to avoid damage to key anatomical features such as nerves, with a particular example being the robotic cochlear implantation minimally invasive approach to cochlear implantation. Use of purpose built surgical robots, electromyography and tissue impedance, stereotactic tracking and drilling force/bone density measurements are all key components, with inputs from these various modalities being dynamically weighted. In the example of robotic cochlear implantation, the inventive concepts are used to provide key surgical guidance so as to avoid damage to the facial nerve and the chorda tympani, among other anatomical features.

Abstract: Provided herein is an inositol polyphosphate oligo alkyl ether compound, or its pharmaceutically acceptable salt, for use in treatment or prevention of a disease associated with formation of calcium salt crystals.

Abstract: The present invention relates to a method for preparing a radioactive polymerizable solution and the solution per se. The solution is prepared by using a cationic radionuclide with a half-life >5 d that is dissolved in an aqueous solution. The radionuclide is extracted into an organic solvent or monomer solution by using a lipophilic ligand for forming a radioactive complex. The ligand is characterized by a ?2:1 ratio of carbon and/or silicon atoms to specific heteroatoms. If an organic solvent is used for extraction, the organic phase obtained is subsequently diluted in a monomer solution to obtain the radioactive polymerizable solution. The invention further relates to the use of said solution in a method for preparing a radioactive object such as a phantom for medical imaging and the object per se.

Abstract: The invention relates to a computer program that when executed on a computer causes a system to execute a method, particularly a computer-implemented method for determining a plurality of functional ocular parameters, with the system comprising an optical system (3) with a display system (4) that is configured to independently project a visual stimulus to a left and a right eye of a test person, an eye-tracking system (5) configured to record a gaze direction (100) and a pupil size (102) of the left as well as the right eye, said computer (2) being configured to control the optical system (3) and to receive recorded data from the eye-tracking system (5), wherein an afferent pupillary defect (APD), particularly a relative afferent pupillary defect (RAPD) is determined from a first trial session consisting of a sequence of first kind of stimuli presented to the left and the right eye of the test person eyes with the display system (4), and wherein a visual field (400) is determined from a second trial session c

Abstract: An aspect of the invention provides a method and a product for determining a modification of the therapy management by using a processor unit which retrieves few data related to the blood glucose measurement performed over a predetermined time period; retrieve the medication delivery parameter executed by the delivery device over said predetermined time period; retrieve from the memory data associated to the CIR of the patient; and determine a modification to the therapy based on at least a part of the retrieved data.

Abstract: The present invention relates to a pharmaceutical nucleic acid agent capable of downregulating or inhibiting the activity of the minor spliceosome (MiS) for use in treatment or prevention of recurrence of cancer. The invention also relates to a method for the diagnosis of cancer.

Abstract: The invention relates to a computer program causing a system with a computer to execute a method, particularly a computer-implemented method for determining at least one functional ocular parameter, namely a visual acuity, wherein the system comprises an optical system with a display system that is configured to independently project a visual stimulus to a left and a right eye of a test person, wherein the visual stimulus comprises a plurality of patches arranged on a background, an eye-tracking system configured to record a gaze direction of the left as well as the right eye, a computer configured to control the optical system and to receive recorded data from the eye-tracking system, the method comprising at least the steps of: executing a trial session for determining the visual acuity, wherein the trial session comprises a plurality of the visual stimuli that are presented, with the optical system to the left and/or the right eye of the test person; recording data during the trial session comprising infor

Abstract: Provided herein is an inositol polyphosphate oligo alkyl ether compound, or its pharmaceutically acceptable salt, for use in treatment or prevention of a disease associated with formation of calcium salt crystals.

Abstract: The present invention relates to a medical device (1) for determining an oxygen saturation in a tissue of a subject, comprising: a sensor (2) comprising a flexible textile (10) comprising a plurality of first optical fibers (11) and a plurality of second optical fibers (12), wherein the first optical and second optical fibers (11, 12) each comprise a first end (11a, 12a) and a second end (11b, 12b), wherein the sensor (2) further comprises a first light generating unit (3) configured to generate and couple light of a first wavelength into the first ends (11a) of the first optical fibers (11) and to generate and couple light of a second wavelength into the second ends (12a) of the first optical fibers (11), the first wavelength being different from the second wavelength, wherein the respective first optical fiber (11) is configured to emit light via a light emitting section (21) of the respective first optical fiber (11) to irradiate tissue of the subject, the light emitting section (21) being arranged between

Abstract: A method for producing non-human conditionally immortalized mast cell progenitors comprises: introducing a nucleic acid molecule comprising an inducible homeobox gene into myeloid progenitor cells, wherein said myeloid progenitor cells are derived from a non-human animal and are engineered to express a heterologous high-affinity IgE receptor alpha subunit (Fc?RI?); and selecting for cells which contain the nucleic acid molecule. The non-human conditionally immortalized mast cell progenitors may be cultured to obtain differentiated mast cells. The mast cells find utility in assays for the determination of IgE mediated allergies.

Abstract: Oligomers can be prepared from bicyclic nucleoside. The nucleosides can be a compound of formula (I) in which each of T1 and T2 is independently OR1 or OR2; R1 is H or a hydroxyl protecting group, R2 is a phosphorus moiety; and Bx is a nucleobase. The compounds, bicyclic nucleosides and the oligomers are useful for the prevention, treatment or diagnosis of muscular dystrophy.

Abstract: Anti-BK virus antibody molecules or binding fragments thereof are disclosed. These Anti-BK virus antibody molecules or binding fragments can be used in the treatment or prevention of BK virus infection and/or BK virus associated disorder.

Abstract: The present invention relates to a magnetic field exposure system for use in exposing organic cells, cellular tissue or at least a part of a subject to a low frequency magnetic field. The system includes a magnetic field generator and amplifier feeding one or more electromagnetic coils configured to produce a magnetic field that varies according to an amplitude modulated signal with a carrier frequency of from 360 to 450. Hz, wherein the modulation frequency is from 0.5 to 100. Hz; and wherein the MF has a field strength of from 0.5 to 250 ?T.

Abstract: The invention relates to nucleic acid products that interfere with or inhibit PROS1 gene expression. It further relates to therapeutic uses of PROS1 inhibition for the treatment of bleeding disorders.

Abstract: Provided herein is an inositol polyphosphate oligo alkyl ether compound, or its pharmaceutically acceptable salt, for use in treatment or prevention of a disease associated with formation of calcium salt crystals.

Abstract: The invention provides an siRNA against protein S for use in a method of treatment of hemophilia. Also within the scope of the present invention is a method for treating hemophilia in a patient in need thereof, comprising administering to the patient a molecule comprising a siRNA according to the invention, and a dosage form for the prevention or treatment of hemophilia, comprising a molecule comprising a siRNA according to the invention.

Abstract: The invention is related to an inositol polyphosphate oligo alkyl ether compound, or its pharmaceutically acceptable salt, for use in treatment or prevention of a disease associated with formation of calcium salt crystals.

Abstract: A cell culturing system includes a docking station, a handling unit, a culturing module and an actuation layer. The culturing module has a culturing well and a culturing membrane separating the culturing well in an apical culturing chamber and a basal culturing chamber. The handling unit removably accommodates the culturing module and the actuation layer. The docking station has a coupling structure for removably holding the handling unit in a predefined position and an actuation feeding channel, wherein, when the handling unit is held by the coupling structure in the predefined position, a first end of the actuation feeding channel is connected to the actuation bore and a second end of the actuation feeding channel is connected to a connector.

Abstract: The invention relates to a method for obtaining a visual field map of an observer, particularly a perimetry method, wherein a plurality of test locations in front of the observer is provided, at each test location of a subset of said plurality a respective perceived sensitivity threshold 5 is measured, wherein at least one light signal is provided at the respective test location, and wherein it is monitored whether said observer observes said at least one light signal, and wherein for each test location a respective estimate of the perceived sensitivity threshold is derived from the previously measured perceived sensitivity thresholds of said subset, and wherein said light signal is provided at a light intensity value derived from the estimate of the 10 perceived sensitivity threshold of said respective test location.